/l (however, cases with LGL o2 Â 10 9 /l that met all other criteria were counted as consistent with the diagnosis of T-LGL leukemia). Each patient met these criteria to be included into the study. The cohort was composed of 24 males and 31 females. Median age was 68.9 years (range: 30.3-84.3 years). For comparison, 79 cases with other T-cell malignancies were analyzed (61 with non-LGL mature T-cell neoplasms and 18 cases with T-ALL; median age: 64.3 years; range: 19.1-86.2 years). Furthermore, 39 cases with reactive conditions were examined. Samples of these patients were referred to our lab with suspected mature T-cell neoplasm, which was excluded by cytomorphology and immunophenotyping (median age: 56.9 years; range: 21.0-87.6 years). All patients gave an informed consent for scientific evaluations, for example, molecular studies. The study was approved by the Internal Review Board of the MLL Munich Leukemia Laboratory and adhered to the tenets of the Declaration of Helsinki. Cytomorphological assessment was based on May-Grü nwald-Giemsa stains. Immunophenotyping was performed in 43/55 cases according to the previously described procedures. 5 The antigens analyzed included CD1a, CD2, CD3, CD4, CD5, CD7, CD8, CD34, CD56, CD57, TCR a/b, TCR g/d and TdT; antibodies were purchased from Immunotech (Marseilles, France). Screening for STAT3 mutations was performed by direct Sanger sequencing of the SH2 domain that is encoded by exon 21 as previously described.
3 TCR rearrangements were assessed by multiplex PCR with subsequent fragment analysis. 6 Dichotomous variables were compared between different groups using the w 2 -test and continuous variables by Student's t-test. Results were considered significant at Po0.05. All the reported P-values are two-sided. No adjustments for multiple comparisons were performed. SPSS version 19.0 (IBM Corporation, Armonk, NY, USA) was used for statistical analysis. Overall, in 40/55 T-LGL leukemia cases (72.7%), 41 STAT3 mutations were detected. All mutations were missense mutations. Six different mutations were observed ( Figure 1 ). Tyr640Phe (n ¼ 18) and Asp661Tyr (n ¼ 13) accounted for 75.6% of all mutations detected. One patient harbored two mutations (Asn647Ile and Tyr640Phe). We also detected a Ile659Leu in one patient, which has not been described previously. 3, 4 There was no association of STAT3 mutations with age, sex and peripheral blood counts in T-LGL leukemia cases (Table 1) . Cases with STAT3 mutations had a stronger expression of CD3 (percentage positive cells, 76 ± 20% vs 58 ± 22%, P ¼ 0.01) and TCRab (68±19% vs 48±20%, P ¼ 0.004). This is probably explained by the significantly elevated clonal size in STAT3-mutated cases compared with STAT3 wild-type cases (percentage positive cells, 31 ± 16% vs 16 ± 13%, P ¼ 0.006). Furthermore, we correlated STAT3 mutation load to clonal size as evaluated by immunophenotyping by Spearman's rank correlation and found a significant positive correlation (correlation coefficient ¼ 0.573, Po0.001). However, the detection of STAT3 mutations was not limited by the size of the pathological T-cell clone, as we were able to detect STAT3 mutations in clones as small as 6% as determined by immunophenotyping. Furthermore, the cohort also contained patients with clonal expansion of T-LGL cells (clonal size up to 73%) that were negative for STAT3 mutations. In addition, we validated nine STAT3 unmutated samples with pathological T-cell clones sizes of 1%-15% by a more sensitive next-generation sequencing approach (Roche 454, Roche Applied Science, Branford, CT, USA) and discovered only one additional STAT3-mutated patient. This patient had a T-cell clone size of 10% and a STAT3 mutation load of 3%. TCR gene usage did not differ between the STAT3-mutated and unmutated cases.
In addition to the T-LGL cases, also seven patients with CLPD-NK were analyzed. A STAT3 mutation was detected in 3/7 cases. One patient had a duplication of one amino acid (Tyr657dup), a mutation Accepted article preview online 4 December 2012; advance online publication, 21 December 2012 so far not observed in T-LGL leukemias (Figure 1 ). However, owing to the limited number of CLPD-NK cases overall, this data needs further confirmation. No STAT3 mutation was identified in a cohort of 118 cases diagnosed with non-LGL mature T-cell neoplasms, T-ALL or reactive conditions. Thus, STAT3 mutations appear to provide a highly specific marker for T-LGL and CLPD-NK leukemias.
We were also interested in whether STAT3 mutations were of any prognostic impact for T-LGL leukemia patients. However, owing to limited follow-up information and the generally good prognosis of LGL leukemia, 7 survival analysis was not informative, as all patients were alive at the time of the present study. Of 11 patients, blood or bone-marrow samples were available at different time points during clinical course. Ten out of eleven patients showed a clinical course with comparable STAT3 mutation load and correlating TCR rearrangement status. One out of eleven patient with a Tyr640Phe mutation in STAT3 showed spontaneous remission of T-LGL leukemia at the molecular level without having received any therapy. Remission was also confirmed by immunophenotyping and cytomorphology. Spontaneous remission of T-LGL has previously been reported, 8, 9 however, to our knowledge, this is the first case of spontaneous remission in STAT3-mutated T-LGL leukemia. Importantly, T-NHL often have an undulating course of disease and the STAT3-mutated clone may have decreased to a non-detectable size.
In conclusion, we were able to confirm the presence of STAT3 mutations in T-LGL as published by Koskela et al., 3 with an even higher frequency of 72.7%. This might be explained by the fact that Koskela et al.
3 included only patients with one major Vb TCR clone to ensure that the cohort is clinically and genetically uniform. In contrast, our cohort consisted of patients with unselected TCR rearrangements. We show that the discovery of STAT3 mutations in T-LGL leukemia has significant diagnostic value as it allows with high specificity to distinguish T-LGL leukemia from other mature T-cell neoplasms and reactive conditions. This strongly supports immunophenotyping and morphology in diagnosing T-LGL leukemia. Chronic lymphocytic leukemia (CLL) is a common neoplasia of B lymphocytes with a heterogeneous clinical course ranging from an indolent disorder, with a normal lifespan, to an aggressive disease and short survival. 1 The genetic mutations and associated molecular alterations that are able to accurately recapitulate the molecular pathogenesis of CLL are only now coming to light. [2] [3] [4] [5] Foremost amongst the mutated genes is SF3B1, a core component of the RNA splicing machinery. SF3B1 mutations were found to be somatically acquired in B10% of CLL patients, and correlate with a more aggressive behavior of the disease. [4] [5] [6] [7] Consistently, the recent identification in myeloid neoplasms of recurrent mutations in SF3B1 and other spliceosome components in a mutually exclusive manner suggests a common functional consequence in the regulation of RNA splicing. [8] [9] [10] Virtually all of the eukaryotic mRNAs are synthesized as precursor molecules that need to be extensively processed in order to serve as a blueprint for proteins. The most prevalent steps are the capping reaction at the 5 0 -end, the removal of intervening sequences by splicing, formation of 3 0 -end poly (A)-tails and the nuclear export of the generated mature mRNA. Other RNA molecules undergo some of these maturation steps. Thus, 5 0 -end capping and transport to the cytosol are necessary to produce functional small nuclear ribonucleoproteins (snRNP), which in turn catalyze mRNA splicing.
11 Although these maturation steps affect most transcripts in the cell, deregulation of splicing has recently been recognized as a driver of oncogenic processes.
12 Moreover, it has been shown that the anti-tumoral mechanism of the drug spliceostatin A involves altered fidelity of splice-site recognition and changes in alternative splicing, particularly of cell-cycle-control genes. 13 With these antecedents, we observed that the list of the 60 genes with the highest corrected mutational frequencies in CLL (RM-CLL genes class 1) contained four genes encoding factors, which has known roles in RNA splicing (SF3B1, SFRS1/SRSF1, U2AF65/U2AF2 and BRUNOL4/ CELF4). 4 In addition, we found three genes encoding RNA-exportmachinery factors (NXF1, XPO1 and DDX3X). 4 This prompted us to investigate the role of mutations affecting the RNA processing machinery, not limited to splicing, in the development of CLL.
To assess the involvement of RNA-processing factors in the development of CLL, we extended our previous high-throughput sequencing experiment in 105 patients to a cohort of 140 patients. Thus, we compared the whole exomes of tumor and normal samples from each patient with the Sidrón algorithm (Supplementary Methods). With this method, we identified 52 somatic mutations in 44 patients affecting 29 genes (Figure 1 and Supplementary Table 1 ). This suggests that mutations on these factors may contribute significantly to CLL development. Consistent with this, only 3 out of the 43 missense mutations identified were predicted as neutral for the function of the protein (Supplementary Table 1) . We compared this frequency with the background proportion of neutral mutations, as estimated with the same method on a set of randomly chosen mutations in genes not related to RNA processing (Supplementary Methods). The proportion of predicted neutral mutations in RNA-processingrelated genes was significantly lower than in the background (3/43 versus 39/122, P ¼ 0.009). The remaining nine mutations are predicted to cause severe effects in six genes through frameshifts, premature stop codons or missed splicing sites. Notably, two of the mutated genes, EIF4A3 and MAGOH, belong to the exon junction complex (EJC). These genes, together with RBM8A and CASC3, form the core of this complex, 14 which suggests that the EJC core might constitute a third target for somatic mutations in CLL.
In spite of this evidence, several of the studied genes show low somatic-mutation frequencies, suggesting that most of the encoded factors may not be driving tumoral progression. Also, the complementation pattern of these mutations does not Accepted article preview online 28 November 2012; advance online publication, 18 December 2012
